Tags:DesignDeviceEventInformationITLocalManagementMediaMedicalMedTechPageProductSkinSocial
This page is intended for US audiences. At Pacira Biosciences, Inc., we are driving innovation to provide ways to manage pain safely and effectively. iovera° is a patented, 510(k)-cleared medical device, which uses targeted cryoanalgesia for immediate and long-lasting pain relief. iovera° treats peripheral nerves to temporarily stop pain signals for up to 90 days and provides pain relief until the nerve regenerates and nerve signaling is restored through an innovative handheld design. The iovera° system is used to destroy tissue during surgical procedures by applying freezing cold. It can also be used to produce lesions in peripheral nervous tissue by the application of cold to the selected site for the blocking of pain. It is also indicated for the relief of pain and symptoms associated with osteoarthritis of the knee for up to 90 days. The iovera° system is not indicated for treatment of central nervous system tissue. iovera° should not be used for people with: cryoglobulinemia, paroxysmal cold hemoglobinuria, cold urticaria, Raynaud’s disease, open and/or infected wounds at or near treatment site. Patients treated with iovera° (a needle-based therapy) may have certain reactions, including but not limited to bruising, swelling, inflammation and/or redness, local pain and/or tenderness, altered feeling at application site. Proper iovera° use (see User Guide) can help reduce or prevent these reactions: in treatment area(s) – skin damage from being exposed to cold/heat, skin darkening/lightening, skin dimples; outside treatment area(s) – muscles may not work/move normally. Adverse event reporting: email drugsafety@pacira.com or call 1-855-793-9727. Product quality complaints: email ioveraCS@icsconnect.com or call 1-800-442-0989. Please don't report such information through this or other social media pages owned by Pacira Biosciences, Inc. If you do report through this page, Pacira reserves the right to contact you for information.

Investors 1

DateNameWebsite
-Valiancevaliance-a...

Mentions in press and media 2

DateTitleDescriptionCategoryAuthorSource
05.03.2019Pacira Pha...No drugs, opioids or narcotics...--medcitynew...
-Pacira Pha...In a bid to expand its efforts...--medcitynew...